Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Pacira Pharm Inc (PCRX)

Pacira Pharm Inc (PCRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 786,326
  • Shares Outstanding, K 46,173
  • Annual Sales, $ 674,980 K
  • Annual Income, $ 41,960 K
  • EBIT $ 156 M
  • EBITDA $ 235 M
  • 60-Month Beta 0.82
  • Price/Sales 1.14
  • Price/Cash Flow 4.23
  • Price/Book 1.03

Options Overview Details

View History
  • Implied Volatility 54.51% ( -2.26%)
  • Historical Volatility 32.50%
  • IV Percentile 46%
  • IV Rank 14.60%
  • IV High 197.17% on 07/15/24
  • IV Low 30.12% on 03/19/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 56
  • Volume Avg (30-Day) 154
  • Put/Call OI Ratio 0.36
  • Today's Open Interest 7,523
  • Open Int (30-Day) 9,017

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate 0.58
  • Number of Estimates 7
  • High Estimate 0.65
  • Low Estimate 0.48
  • Prior Year 0.71
  • Growth Rate Est. (year over year) -18.31%

Price Performance

See More
Period Period Low Period High Performance
1-Month
16.00 +8.88%
on 11/18/24
18.34 -5.02%
on 11/08/24
+0.09 (+0.52%)
since 10/21/24
3-Month
12.61 +38.14%
on 09/12/24
18.34 -5.02%
on 11/08/24
+3.57 (+25.78%)
since 08/21/24
52-Week
11.16 +56.04%
on 08/13/24
35.95 -51.54%
on 01/08/24
-9.24 (-34.66%)
since 11/21/23

Most Recent Stories

More News
Pacira BioSciences Reports Sustained Pain Relief in Osteoarthritis with Gene Therapy Candidate PCRX-201 in Upcoming ACR Presentation

Pacira BioSciences reports positive data on gene therapy PCRX-201 for knee osteoarthritis, showing sustained pain relief for 104 weeks.Quiver AI SummaryPacira BioSciences, Inc. recently revealed promising...

PCRX : 17.48 (+2.64%)
Pacira Announces 104-Week Safety and Efficacy Data Following Local Administration of PCRX-201 for Moderate to Severe Osteoarthritis of the Knee

PCRX : 17.48 (+2.64%)
Pacira BioSciences to Participate in Fireside Chat at Two Upcoming Healthcare Conferences

PCRX : 17.48 (+2.64%)
Pacira: Q3 Earnings Snapshot

Pacira: Q3 Earnings Snapshot

PCRX : 17.48 (+2.64%)
Pacira BioSciences Reports Third Quarter 2024 Financial Results

PCRX : 17.48 (+2.64%)
Centers for Medicare and Medicaid Services (CMS) Establishes Additional Payment for iovera in Outpatient Settings

PCRX : 17.48 (+2.64%)
Pacira to Report Third Quarter 2024 Financial Results on Wednesday November 6, 2024

PCRX : 17.48 (+2.64%)
Are Options Traders Betting on a Big Move in Pacira BioSciences (PCRX) Stock?

Investors in Pacira BioSciences, Inc. PCRX need to pay close attention to the stock based on moves in the options market lately. That is because the Nov 15, 2024 $25.00 Call had some of the highest implied...

PCRX : 17.48 (+2.64%)
Pacira BioSciences Appoints Shawn Cross as Chief Financial Officer

PCRX : 17.48 (+2.64%)
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

PCRX : 17.48 (+2.64%)

Business Summary

Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on the development, commercialization and manufacture of proprietary pharmaceutical products primarily for use in hospitals and ambulatory surgery centers. These products are developed using the company's proprietary DepoFoam drug...

See More

Key Turning Points

3rd Resistance Point 18.02
2nd Resistance Point 17.64
1st Resistance Point 17.34
Last Price 17.48
1st Support Level 16.66
2nd Support Level 16.28
3rd Support Level 15.97

See More

52-Week High 35.95
Fibonacci 61.8% 26.48
Fibonacci 50% 23.56
Fibonacci 38.2% 20.63
Last Price 17.48
52-Week Low 11.16

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar